C4 Therapeutics (CCCC) EBITDA Margin Growth (3y) (2022 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) EBITDA Margin Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 7,045.00 |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -1,934.00 |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 7,261.00 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 9,003.00 |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -2,649.00 |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 30,461.00 |
| 10 | C4 Therapeutics | 492.73 Mn | 239.06 Mn | - | 101,233.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 101,233.00 |
| Mar 31, 2026 | 51,213.00 |
| Dec 31, 2025 | 113,163.00 |
| Sep 30, 2025 | 17,459.00 |
| Jun 30, 2025 | -24,304.00 |
| Mar 31, 2025 | 691.00 |
| Dec 31, 2024 | -65,242.00 |
| Sep 30, 2024 | 10,148.00 |
| Jun 30, 2024 | 4,752.00 |
| Mar 31, 2024 | -78,401.00 |
| Dec 31, 2023 | -91,892.00 |
| Sep 30, 2023 | -3,393.00 |
| Jun 30, 2023 | -129,791.00 |
| Mar 31, 2023 | -78,275.00 |
| Dec 31, 2022 | -121,383.00 |
| Sep 30, 2022 | -29,457.00 |